17,261 trials
Chronic Hepatitis C
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) — 17; 19; 14; 13 Participants
Ocular Anesthesia
Primary: Subjective Injection Pain — 7.0; 3.1; 3.0; 1.8 units on a scale
Autism Spectrum Disorders
Primary: Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2) — -1.6; -0.4 units on a scale — p=0.0028
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 (ADHD-RS-5) Total Score — -11.04; -10.38 units on a scale
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 (ADHD-RS-5) Total Score — -9.17; -11.34 units on a scale
Melanoma
Primary: Number of Adverse Events — 51; 45 Number of events in treatment group
Major Depressive Disorder
Primary: Number of Responders 24-hours Post-ketamine Infusion — 3; 1; 3; 2 participants
Cystic Fibrosis
Primary: 6 Minute Walk Distance — 25.2; 0.75 meters
Breast Cancer
Primary: Objective Response Rate (ORR) — 33 Participants
Basal Cell Nevus Syndrome
Primary: Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline — 51.29; 26.63; 21.82 percentage…
Healthy Volunteers · Brain Lesion
Primary: Pharmacokinetic (PK) Parameter Cmax — 248.7; 524.5; 698.7; 992.0 µg/mL
Head and Neck Cancer
Primary: Progression-free Survival — 54.2 months
Sexual Dysfunctions, Psychological · Hypoactive Sexual Desire Disorder · Erectile Dysfunctions
Primary: Number of Participants With a Score of ≤2 (Much/Very Much Improved) on the Clinical Global Impression Scale Adapted for Sexual Function (CGI-SF) at Week 6 Between…
Paroxysmal Nocturnal Hemoglobinuria
Primary: Change From Baseline in Lactate Dehydrogenase — -15.9 Units/Liter — p=<0.001
Adrenoleukodystrophy · Metachromatic Leukodystrophy · Globoid Cell Leukodystrophy
Primary: Number of Patients With Donor Cell Engraftment — 26 Participants